Department of Surgery, Fukuoka Higashi Medical Center, 1-1-1 Chidori, Koga, Japan.
Breast Cancer. 2011 Jan;18(1):37-41. doi: 10.1007/s12282-010-0200-2. Epub 2010 Mar 4.
Molecular-targeting drugs able to treat breast cancer expressing epidermal growth factor receptor (EGFR) would be clinically valuable. The aim of the current study was to determine the further significance of immunohistochemical expression of EGFR in breast cancer.
The immunohistochemical expression of EGFR was examined in 37 women with breast cancer who had been treated with surgical resection. Relationship of EGFR expression and clinicopathological characteristics was investigated.
EGFR expression proved to be comparatively more frequent among triple-negative (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative) breast cancers (P = 0.067).
Knowledge of a patient's immunohistochemical EGFR expression, which could be one of the key molecular findings related to molecular-targeting therapy, might be useful information to treat triple-negative breast cancer.
能够治疗表达表皮生长因子受体（EGFR）的乳腺癌的分子靶向药物在临床上具有重要价值。本研究旨在确定 EGFR 在乳腺癌中的免疫组织化学表达的进一步意义。
对 37 名接受手术切除治疗的乳腺癌女性患者进行 EGFR 的免疫组织化学表达检测。并研究 EGFR 表达与临床病理特征之间的关系。
EGFR 表达在三阴性（雌激素受体阴性、孕激素受体阴性和人表皮生长因子受体 2 阴性）乳腺癌中更为常见（P=0.067）。
了解患者的 EGFR 免疫组织化学表达（这可能是与分子靶向治疗相关的关键分子发现之一）可能是治疗三阴性乳腺癌的有用信息。
